Surgical Science Sweden AB (publ)

OM:SUS Stock Report

Market Cap: SEK 1.6b

Surgical Science Sweden Valuation

Is SUS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of SUS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: SUS (SEK31.64) is trading below our estimate of future cash flow value (SEK133.07)

Significantly Below Future Cash Flow Value: SUS is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SUS?

Key metric: As SUS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SUS. This is calculated by dividing SUS's market cap by their current earnings.
What is SUS's PE Ratio?
PE Ratio24.2x
EarningsSEK 66.82m
Market CapSEK 1.61b

Price to Earnings Ratio vs Peers

How does SUS's PE Ratio compare to its peers?

The above table shows the PE ratio for SUS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average40.4x
CRAD B C-Rad
87.2x45.53%SEK 908.3m
CEVI CellaVision
23.3x14.51%SEK 3.6b
STIL Stille
36.6x21.52%SEK 2.0b
CARE Careium
14.7x25.24%SEK 486.5m
SUS Surgical Science Sweden
24.2x27.95%SEK 1.6b

Price-To-Earnings vs Peers: SUS is good value based on its Price-To-Earnings Ratio (24.2x) compared to the peer average (40.3x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does SUS's PE Ratio compare vs other companies in the European Medical Equipment Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
SUS 24.2xIndustry Avg. 23.5xNo. of Companies15PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: SUS is expensive based on its Price-To-Earnings Ratio (24.2x) compared to the European Medical Equipment industry average (23.5x).

Price to Earnings Ratio vs Fair Ratio

What is SUS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SUS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio24.2x
Fair PE Ratio25.6x

Price-To-Earnings vs Fair Ratio: SUS is good value based on its Price-To-Earnings Ratio (24.2x) compared to the estimated Fair Price-To-Earnings Ratio (25.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SUS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 31.64
SEK 57.60
+82.05%
34.77%SEK 88.00SEK 40.00n/a5
Apr ’27SEK 31.92
SEK 57.60
+80.45%
34.77%SEK 88.00SEK 40.00n/a5
Mar ’27SEK 32.30
SEK 57.60
+78.33%
34.77%SEK 88.00SEK 40.00n/a5
Feb ’27SEK 27.02
SEK 62.20
+130.20%
50.43%SEK 118.00SEK 33.00n/a5
Jan ’27SEK 32.50
SEK 64.20
+97.54%
47.53%SEK 118.00SEK 33.00n/a5
Dec ’26SEK 34.40
SEK 77.60
+125.58%
56.74%SEK 142.00SEK 33.00n/a5
Nov ’26SEK 84.00
SEK 149.60
+78.10%
14.59%SEK 185.00SEK 120.00n/a5
Oct ’26SEK 88.10
SEK 163.00
+85.02%
14.85%SEK 185.00SEK 120.00n/a5
Sep ’26SEK 97.00
SEK 163.00
+68.04%
14.85%SEK 185.00SEK 120.00n/a5
Aug ’26SEK 144.80
SEK 183.40
+26.66%
9.48%SEK 200.00SEK 150.00n/a5
Jul ’26SEK 151.10
SEK 187.00
+23.76%
10.24%SEK 205.00SEK 150.00n/a6
Jun ’26SEK 143.90
SEK 187.00
+29.95%
10.24%SEK 205.00SEK 150.00n/a6
May ’26SEK 137.70
SEK 197.17
+43.19%
6.84%SEK 215.00SEK 180.00n/a6
Apr ’26SEK 126.90
SEK 197.17
+55.37%
6.84%SEK 215.00SEK 180.00SEK 31.926
Mar ’26SEK 157.50
SEK 193.00
+22.54%
9.39%SEK 215.00SEK 165.00SEK 32.306
Feb ’26SEK 172.90
SEK 192.17
+11.14%
10.01%SEK 225.00SEK 165.00SEK 27.026
Jan ’26SEK 155.90
SEK 192.17
+23.26%
10.01%SEK 225.00SEK 165.00SEK 32.506
Dec ’25SEK 148.20
SEK 192.17
+29.67%
10.01%SEK 225.00SEK 165.00SEK 34.406
Nov ’25SEK 127.90
SEK 188.17
+47.12%
15.27%SEK 225.00SEK 135.00SEK 84.006
Oct ’25SEK 122.90
SEK 188.17
+53.11%
15.27%SEK 225.00SEK 135.00SEK 88.106
Sep ’25SEK 124.00
SEK 189.00
+52.42%
14.39%SEK 225.00SEK 140.00SEK 97.006
Aug ’25SEK 127.90
SEK 204.00
+59.50%
19.07%SEK 260.00SEK 140.00SEK 144.806
Jul ’25SEK 125.00
SEK 204.00
+63.20%
19.07%SEK 260.00SEK 140.00SEK 151.106
Jun ’25SEK 144.60
SEK 208.17
+43.96%
15.69%SEK 260.00SEK 165.00SEK 143.906
May ’25SEK 157.10
SEK 221.50
+40.99%
13.62%SEK 260.00SEK 165.00SEK 137.706
Apr ’25SEK 151.70
SEK 222.33
+46.56%
13.70%SEK 260.00SEK 165.00SEK 126.906
SEK 57.6
Fair Value
45.1% undervalued intrinsic discount
5
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/10 17:55
End of Day Share Price 2026/04/10 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Surgical Science Sweden AB (publ) is covered by 5 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Simon JonssonBerenberg
Simon LarssonDanske Bank
Kristofer Liljeberg-SvenssonDNB Carnegie